Overview

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This clinical research study will test the safety and efficacy of the investigational medication MAU868, compared to a placebo, in patients who have had a kidney transplant who have active BK virus.
Phase:
Phase 2
Details
Lead Sponsor:
Amplyx Pharmaceuticals